Search

Czeslaw H Radziejewski

from Westborough, MA
Age ~74
Get Report
Also known as:
Czeslaw M Radziejewski, Czeslow H Radziejewski, Czestaw H Radziejewski, Czestow H Radziejewski, Czwslaw H Radziejewski, R I
Phone and address:
3 Blossom Ct #3, Westboro, MA 01581
Related to:
Czeslaw H Radziejewska, 74Natalia Radziejewska, 47Elzbieta Radziejewska, 75
Connected to:
David R Radziej, 63Alexandra Radziewicz, 44Clifford J Radziewicz, 69Irene A Radziewicz, 94Mark R Radziewicz, 63Melissa Radziewicz, 61Patricia Radziewicz, 96Robyn D Radziewicz, 36Cindy L Radzik, 68Kevin R Radzik, 45

Czeslaw Radziejewski Phones & Addresses

  • 3 Blossom Ct #3, Westborough, MA 01581
  • 323 Heritage Hls, Somers, NY 10589
  • 323B Heritage Hls, Somers, NY 10589
  • White Plains, NY
  • New York, NY
  • Westchester, NY
  • 3 Blossom Ct, Westborough, MA 01581

Work

Company: Syner-g pharma cmc consulting, llc Oct 2019 Position: Senior cmc consultant

Education

School / High School: The Rockefeller University 1982 to 1989

Skills

Protein Chemistry • Biopharmaceuticals • Monoclonal Antibodies • Chromatography • Biotechnology • Mass Spectrometry • Protein Purification • Antibodies • Characterization • Drug Discovery • Chemistry • Validation • Drug Development • Hplc • Technology Transfer • Biochemistry • Gmp • Biophysics • Process Simulation • Purification • Lc Ms • Glp • Protein Expression • Analytical Chemistry • Cell • In Vitro • High Throughput Screening • Lims • Lifesciences • Western Blotting • Protein Characterization • Sds Page • Cmc • Proteomics • Elisa • Electrophoresis • Contract Manufacturing • Analytical Methods Development • Science • Immunology • Drug Design • Pcr • Fluorescence • Uv Vis • Qpcr • Project Portfolio Management • Team Management • Biomarkers • Medicinal Chemistry • Uv/Vis

Languages

English • Polish

Interests

Science and Technology • Education • Arts and Culture • Environment

Industries

Biotechnology

Resumes

Resumes

Czeslaw Radziejewski Photo 1

Worcester, Massachusetts

View page
Location:
Westborough, MA
Industry:
Biotechnology
Work:
Syner-G Pharma Cmc Consulting, Llc
Senior Cmc Consultant
Abbvie Bioresearch Center Oct 2017 - Oct 2019
Research Fellow, Biophysical Chemistry
Abbvie Bioresearch Center Oct 2017 - Oct 2019
Senior Principal Research Scientist Biophysical Chemistry
Abbvie Bioresearch Center Aug 2006 - May 2016
Associate Director Protein Analytics
Regeneron Pharmaceuticals, Inc. Jan 2005 - Oct 2005
Senior Director
Education:
The Rockefeller University 1982 - 1989
University of Chicago 1981 - 1982
Center of Molecular and Macromolecular Studies 1975 - 1980
Doctorates, Doctor of Philosophy, Chemistry University of Chicago
Rockefeller University
Skills:
Protein Chemistry
Biopharmaceuticals
Monoclonal Antibodies
Chromatography
Biotechnology
Mass Spectrometry
Protein Purification
Antibodies
Characterization
Drug Discovery
Chemistry
Validation
Drug Development
Hplc
Technology Transfer
Biochemistry
Gmp
Biophysics
Process Simulation
Purification
Lc Ms
Glp
Protein Expression
Analytical Chemistry
Cell
In Vitro
High Throughput Screening
Lims
Lifesciences
Western Blotting
Protein Characterization
Sds Page
Cmc
Proteomics
Elisa
Electrophoresis
Contract Manufacturing
Analytical Methods Development
Science
Immunology
Drug Design
Pcr
Fluorescence
Uv Vis
Qpcr
Project Portfolio Management
Team Management
Biomarkers
Medicinal Chemistry
Uv/Vis
Interests:
Science and Technology
Education
Arts and Culture
Environment
Languages:
English
Polish

Publications

Us Patents

Tie-2 Ligands

View page
US Patent:
6433143, Aug 13, 2002
Filed:
Sep 16, 1999
Appl. No.:
08/817318
Inventors:
Samuel Davis - New York NY
Joanne Bruno - Bloomingdale NJ
Mitchell Goldfarb - River Edge NJ
Thomas H. Aldrich - Ossining NY
Peter C. Maisonpierre - Croton NY
Czeslaw Radziejewski - Somers NY
Pamela F. Jones - Leeds, GB
George D. Yancopoulos - Yorktown Heights NY
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C07K 1452
US Classification:
530351, 530402, 435 697, 435471, 435 712, 435325, 4352523, 43525411, 4353201
Abstract:
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body, which specifically binds a human TIE-2 ligand. The invention also provides an antibody that specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

Tie-2 Ligands, Methods Of Making And Uses Thereof

View page
US Patent:
7063840, Jun 20, 2006
Filed:
Jun 24, 2002
Appl. No.:
10/179615
Inventors:
Samuel Davis - New York NY, US
Joanne Bruno - Bloomingdale NJ, US
Mitchell Goldfarb - River Edge NJ, US
Thomas H. Aldrich - Ossining NY, US
Peter C. Maisonpierre - Croton NY, US
Czeslaw Radziejewski - Somers NY, US
Pamela F. Jones - Leeds, GB
George D. Yancopoulos - Yorktown Heights NY, US
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C07K 16/24
A61K 39/395
US Classification:
4241391, 4241411, 4241451, 4241781, 5303871, 5303881, 5303873, 53038823, 5303892
Abstract:
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

Tie-2 Ligands, Methods Of Making And Uses Thereof

View page
US Patent:
20020173627, Nov 21, 2002
Filed:
Jun 24, 2002
Appl. No.:
10/179744
Inventors:
Samuel Davis - New York NY, US
Joanne Bruno - Bloomingdale NJ, US
Mitchell Goldfarb - River Edge NJ, US
Thomas Aldrich - Ossining NY, US
Peter Maisonpierre - Croton NY, US
Czeslaw Radziejewski - Somers NY, US
Pamela Jones - Leeds, GB
George Yancopoulos - Yorktown Heights NY, US
International Classification:
C07K014/715
C07H021/04
C12P021/02
C12N005/06
US Classification:
530/350000, 536/023200, 435/069100, 435/325000, 435/320100
Abstract:
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

Tie-2 Ligands, Methods Of Making And Uses Thereof

View page
US Patent:
20030166858, Sep 4, 2003
Filed:
Jun 24, 2002
Appl. No.:
10/179820
Inventors:
Samuel Davis - New York NY, US
Joanne Bruno - Bloomingdale NJ, US
Mitchell Goldfarb - River Edge NJ, US
Thomas Aldrich - Ossining NY, US
Peter Maisonpierre - Croton NY, US
Czeslaw Radziejewski - Somers NY, US
Pamela Jones - Leeds, GB
George Yancopoulos - Yorktown Heights NY, US
International Classification:
C07K014/705
C07H021/04
C12P021/02
C12N005/06
US Classification:
530/350000, 435/069100, 435/320100, 435/325000, 536/023500
Abstract:
The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.

Modification Assisted Profiling (Map) Methodology

View page
US Patent:
20040101920, May 27, 2004
Filed:
Oct 31, 2003
Appl. No.:
10/699361
Inventors:
Czeslaw Radziejewski - Somers NY, US
Ergang Shi - Ossing NY, US
International Classification:
G01N033/53
G01N033/537
G01N033/543
US Classification:
435/007920
Abstract:
Methods of utilizing a biosensor platform for the purpose of studying macromolecule interactions is provided. Also provided are methods of sorting monoclonal antibodies directed against a particular antigen into functional groups wherein each group exhibits a characteristic binding profile to the antigen.

Stable Antibody Compositions And Methods Of Stabilizing Same

View page
US Patent:
20100172862, Jul 8, 2010
Filed:
Nov 24, 2009
Appl. No.:
12/625057
Inventors:
Ivan R. Correia - Winchester MA, US
Czeslaw H. Radziejewski - Westborough MA, US
Wolfgang Fraunhofer - Shrewsbury MA, US
Nicholas W. Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
Assignee:
ABBOTT LABORATORIES - Abbott Park IL
International Classification:
A61K 38/20
C07K 16/18
A61K 39/395
A61K 38/19
A61K 38/21
A61P 37/04
US Classification:
424 852, 5303871, 4241301, 4241411, 424 851, 424 856
Abstract:
The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.

Assay For Ligands To Tyrosine Kinase Receptors

View page
US Patent:
60226943, Feb 8, 2000
Filed:
Dec 29, 1997
Appl. No.:
8/998972
Inventors:
Czeslaw Radziejewski - Somers NY
Ajay Shrivastava - Fairfield CT
George D. Yancopoulos - Yorktown Heights NY
Assignee:
Regeneron Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
C12Q 100
US Classification:
435 71
Abstract:
The present invention provides for a screen for a polypeptide ligand that can bind to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor and that can promote a differential function and/or influence the phenotype, such as growth and/or proliferation, of cells that bear the receptor. The present invention also provides a method of screening for a molecule capable of competing with collagen for binding to the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor comprising contacting a sample suspected of containing the molecule with the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor in the presence of collagen under conditions in which the collagen is capable of binding to the extracellular domain and detecting binding of the molecule to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor extracellular domain. The invention further contemplates the utilization of collagen to support the growth, survival, or differentiation of Tyro-10 (DDR-2) or NEP (DDR-1) expressing cells.

Stable Antibody Compositions And Methods Of Stabilizing Same

View page
US Patent:
20150071944, Mar 12, 2015
Filed:
Nov 6, 2014
Appl. No.:
14/534776
Inventors:
- NORTH CHICAGO IL, US
Czeslaw H. Radziejewski - Westborough MA, US
Wolfgang Fraunhofer - Shrewbury MA, US
Nicholas William Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
International Classification:
C07K 16/24
A61K 47/26
A61K 47/22
A61K 39/395
US Classification:
4241581
Abstract:
The invention provides compositions and methods for inhibiting fractionation of immunoglobulins comprising a lambda light chain based on the observation that iron, in the presence of histidine, results in increased fragmentation of a recombinant fully human IgG molecule containing a lambda light chain due to cleavage in the hinge region. The invention further provides an aqueous pharmaceutical formulation comprising an antibody, or antigen-binding portion thereof, that binds the p40 subunit of IL-12/IL-23 and a buffer system comprising histidine, wherein the formulation has enhanced stability, including enhanced resistance to fragmentation.
Control profile
Czeslaw H Radziejewski from Westborough, MA, age ~74 Get Report